Alpha Tau Medical (NASDAQ:DRTS) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a report published on Wednesday, Benzinga reports. They currently have a $9.00 price target on the stock.

Alpha Tau Medical Stock Up 23.4 %

Alpha Tau Medical stock opened at $2.53 on Wednesday. Alpha Tau Medical has a 52-week low of $1.75 and a 52-week high of $4.37. The firm has a 50 day moving average price of $2.46 and a two-hundred day moving average price of $2.81. The firm has a market cap of $176.27 million, a price-to-earnings ratio of -6.17 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.60 and a current ratio of 11.60.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, May 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Equities analysts predict that Alpha Tau Medical will post -0.5 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Levin Capital Strategies L.P. lifted its holdings in shares of Alpha Tau Medical by 288.4% in the 4th quarter. Levin Capital Strategies L.P. now owns 330,123 shares of the company’s stock worth $994,000 after purchasing an additional 245,123 shares in the last quarter. Private Advisor Group LLC bought a new stake in shares of Alpha Tau Medical during the fourth quarter worth about $176,000. Satovsky Asset Management LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter worth about $176,000. Telemus Capital LLC bought a new position in Alpha Tau Medical in the 4th quarter valued at about $89,000. Finally, USAdvisors Wealth Management LLC bought a new stake in Alpha Tau Medical during the 1st quarter worth approximately $30,000. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.